Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer
Any treatment protocol needs constant reappraisal. Neoadjuvant chemotherapy (Neo) is the use of chemo for ovarian cancer patients before surgery, at the time of initial presentation. First used for patients who were either too frail or had too big a tumour for surgery, Neo has become more frequent.
Previous studies in 2010 showed no disadvantage in survival. Neo is often preferred because the subsequent surgery is more straightforward with fewer complications. Also logistically it make scheduling surgery simpler. Although generally there has been an increase in the use of Neo, some treatment centres have not done so.
This retrospective study looks at 20,000+ patients from 300+ centres during the period 2004-2015. No difference was seen in overall survival between centres which increased Neo compared to those that did not. The mortality at one year was less in centres where Neo use increased.
No comments:
Post a Comment